Fate Therapeutics: Getting There, But Perpetually (NASDAQ:FATE)


Country road

Igor Alecsander/E+ via Getty Images

I covered Fate Therapeutics (NASDAQ:FATE) in a rare “sell” rated article in March, and the stock has gone down 50%, validating my negative stance if not my arguments for the same. I noted very early in the



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *